IKT (STOCKS)
Inhibikase Therapeutics, Inc. Common Stock
$1.740000
+0.040000 (+2.35%)
Prev close: $1.700000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Mark T. Iwicki
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $224.46M
- Employees
- 16
- P/E (TTM)
- -3.47
- P/B (TTM)
- 1.30
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.09 | $-0.10 | +0.0142 | +13.63% |
|
Sep 2025 (Q3)
|
$-0.13 | $-0.13 | +0.0013 | +0.99% |
|
Jun 2025 (Q2)
|
$-0.11 | $-0.09 | -0.0191 | -21.01% |
|
Mar 2025 (Q1)
|
$-0.17 | $-0.11 | -0.0639 | -60.23% |
Financial Statements
| Revenues | $3.72M |
| Benefits Costs and Expenses | $3.76M |
| Costs And Expenses | $51.97M |
| Operating Expenses | $55.69M |
| Selling, General, and Administrative Expenses | $23.56M |
| Research and Development | $29.79M |
| Other Operating Expenses | $2.34M |
| Operating Income/Loss | -$51.97M |
| Income/Loss From Continuing Operations After Tax | -$48.26K |
| Income/Loss From Continuing Operations Before Tax | -$48.26K |
| Income Tax Expense/Benefit | $0.00 |
| Interest Income/Expense After Provision For Losses | $3.72M |
| Interest Income/Expense Operating, Net | $3.72M |
| Net Income/Loss | -$48.26M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$48.26M |
| Net Income/Loss Available To Common Stockholders, Basic | -$48.26M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$0.49 |
| Diluted Earnings Per Share | -$0.49 |
| Basic Average Shares | 98,310,190 |
| Diluted Average Shares | 98,310,190 |
| Assets | $181.20M |
| Current Assets | $180.11M |
| Prepaid Expenses | $1.00M |
| Other Current Assets | $179.11M |
| Noncurrent Assets | $1.10M |
| Fixed Assets | $0.00 |
| Non-current Prepaid Expenses | $1.00M |
| Other Non-current Assets | $95.12K |
| Liabilities | $8.30M |
| Current Liabilities | $8.30M |
| Accounts Payable | $1.16M |
| Other Current Liabilities | $7.14M |
| Noncurrent Liabilities | $0.00 |
| Equity | $172.90M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $172.90M |
| Liabilities And Equity | $181.20M |
| Net Cash Flow From Operating Activities | -$27.79M |
| Net Cash Flow From Operating Activities, Continuing | -$27.79M |
| Net Cash Flow From Investing Activities | $2.05M |
| Net Cash Flow From Investing Activities, Continuing | $2.05M |
| Net Cash Flow From Financing Activities | $108.46M |
| Net Cash Flow From Financing Activities, Continuing | $108.46M |
| Net Cash Flow | $82.73M |
| Net Cash Flow, Continuing | $82.73M |
| Other Comprehensive Income/Loss | -$48.20M |